Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803288 | 0.89 | IDH1 (0.50) | IDH1FAAHKDM4ECYP2C19GRIN1 | |
| SCHEMBL3657715 | 0.87 | DRD2 (0.47) | IDH1FAAHKDM4ECYP2C19GRIN1 | |
| SCHEMBL3659200 | 0.87 | DRD2 (0.47) | IDH1FAAHKDM4ECYP2C19GRIN1 | |
| SCHEMBL3657710 | 0.87 | DRD2 (0.47) | IDH1FAAHKDM4ECYP2C19GRIN1 | |
| SCHEMBL5108390 | 0.85 | KDM4E (0.41) | IDH1FAAHKDM4ECYP2C19L3MBTL1 | |
| SCHEMBL369170 | 0.85 | KDM4E (0.41) | IDH1FAAHKDM4ECYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL3241637 | 0.83 | KDM4E (0.40) | IDH1FAAHKDM4ECYP2C19L3MBTL1 | |
| SCHEMBL923515 | 0.82 | FAAH (0.42) | IDH1FAAHKDM4EGRIN1GRIN2B | |
| SCHEMBL17803299 | 0.81 | IDH1 (0.53) | IDH1FAAHKDM4ECYP2C19L3MBTL1 | |
| Hydrochloric Acid SCHEMBL2883763 | 0.79 | OPRL1 (0.45) | IDH1FAAHKDM4ECYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | IDH1 314/4885FAAH 3609/4885KDM4E 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.